{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tamoxifen-managing-adverse-effects/how-this-topic-was-developed/organizational-behavioural-financial-barriers/","result":{"pageContext":{"chapter":{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers","depth":2,"htmlHeader":"<!-- begin field f8e5d395-b09a-4e5c-99a2-a7f3000e3bbf --><h2>Organizational, behavioural and financial barriers</h2><!-- end field f8e5d395-b09a-4e5c-99a2-a7f3000e3bbf -->","summary":null,"htmlStringContent":"<!-- begin item e819c5f1-534c-4451-868d-a7f3000c45d5 --><!-- begin field 2def09de-82a9-497f-ae7c-a7f3000e3bbf --><h2>Our policy</h2><!-- end field 2def09de-82a9-497f-ae7c-a7f3000e3bbf --><!-- begin field 72e8c960-8c23-42cc-b036-a7f3000e3bbf --><p>The CKS literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.</p><ul><li>Feasibility<ul><li>Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.</li></ul></li><li>Organizational and Financial Impact Analysis</li><li>Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.<ul><li>Eligible population</li><li>Current interventions</li><li>Likely uptake of new intervention or recommendation</li><li>Cost of the current or new intervention mix</li><li>Impact on other costs</li><li>Condition-related costs</li><li>In-direct costs and service impacts</li><li>Time dependencies</li></ul></li><li>Cost-effectiveness or cost-benefit analysis studies are identified where available. </li></ul><p>We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines. When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.</p><!-- end field 72e8c960-8c23-42cc-b036-a7f3000e3bbf --><!-- end item e819c5f1-534c-4451-868d-a7f3000c45d5 -->","topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","lastRevised":"Last revised in November 2019","chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","fullItemName":"Management","slug":"management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}